Skip to main content

Advertisement

SpringerLink
Log in

Bronchopulmonary dysplasia: An update

  • Symposium: Neonatology II Evidence and Experience in Neonatal Medicine
  • Published:
The Indian Journal of Pediatrics Aims and scope Submit manuscript

Abstract

Bronchopulmonary dysplasia (BPD) is a chronic lung disease associated with premature birth and characterized by early lung injury. Over the past 4 decades, there have been significant changes in its definition, pathology and radiological findings as well as management of BPD. Management of the acute phase and later stages of this lung disease continue to evolve. Use of non-invasive ventilatory techniques, recombinant human SOD and CC10 and inhaled NO are some novel approaches that are being studied. Adequate nutrition is vital to optimize lung growth and repair. The widely accepted practice of prophylaxis against viral infections has markedly decreased the rates of rehospitalization. Infants with BPD, however, continue to have significant pulmonary and neurodevelopmental sequelae. Unraveling the genetic contribution to BPD will potentially pave the way to improved preventive and therapeutic approaches.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Jobe AH, Bancalari E. Bronchopulmonary dysplasia. Am J Respir Crit Care Med 2001; 163: 17231729.

    PubMed  CAS  Google Scholar 

  2. Northway WH, Jr., Rosan RC, Porter DY. Pulmonary disease following respirator therapy of hyaline-membrane disease. Bronchopulmonary dysplasia. N Engl J Med 1967; 276: 357368.

    Article  PubMed  Google Scholar 

  3. Ehrenkranz RA, Walsh MC, Vohr BR et al. Validation of the National Institutes of Health consensus definition of bronchopulmonary dysplasia. Pediatrics 2005; 116: 13531360.

    Article  PubMed  Google Scholar 

  4. Rosan RC. Hyaline membrane disease and a related spectrum of neonatal pneumopathies. Perspect Pediatr Pathol 1975; 2: 1560.

    PubMed  CAS  Google Scholar 

  5. Stocker JT. Pathologic features of long-standing healed bronchopulmonary dysplasia: a study of 28 3-to 40-month-old infants. Hum Pathol 1986; 17: 943961.

    PubMed  CAS  Google Scholar 

  6. Husain AN, Siddiqui NH, Stocker JT. Pathology of arrested acinar development in postsurfactant bronchopulmonary dysplasia. Hum Pathol 1998; 29: 710717.

    Article  PubMed  CAS  Google Scholar 

  7. De Paepe ME, Mao Q, Powell J et al. Growth of pulmonary microvasculature in ventilated preterm infants. Am J Respir Crit Care Med 2006; 173: 204211.

    Article  PubMed  Google Scholar 

  8. Coalson JJ. Pathology of new bronchopulmonary dysplasia. Semin Neonatol 2003; 8: 7381.

    Article  PubMed  Google Scholar 

  9. Thibeault DW, Mabry SM, Norberg M, Truog WE, Ekekezie, II. Lung microvascular adaptation in infants with chronic lung disease. Biol Neonate 2004; 85: 273282.

    Article  PubMed  Google Scholar 

  10. Bhandari A, Bhandari V. Pathogenesis, pathology and pathophysiology of pulmonary sequelae of bronchopulmonary dysplasia in premature infants. Front Biosci 2003; 8: e370380.

    PubMed  CAS  Google Scholar 

  11. Bhandari V, Bizzarro MJ, Shetty AH et al. Familial and genetic susceptibility to major neonatal morbidities in preterm twins. Pediatrics 2006; 117: 19011906.

    Article  PubMed  Google Scholar 

  12. Furman L, Baley J, Borawski-Clark E, Aucott S, Hack M. Hospitalization as a measure of morbidity among very low birth weight infants with chronic lung disease. J Pediatr 1996; 128: 447452.

    Article  PubMed  CAS  Google Scholar 

  13. Northway WH, Jr., Moss RB, Carlisle KB et al. Late pulmonary sequelae of bronchopulmonary dysplasia. N Engl J Med 1990; 323: 17931799.

    Article  PubMed  Google Scholar 

  14. Aquino SL, Schechter MS, Chiles C, Ablin DS, Chipps B, Webb WR. High-resolution inspiratory and expiratory CT in older children and adults with bronchopulmonary dysplasia. AJR Am J Roentgenol 1999; 173: 963967.

    PubMed  CAS  Google Scholar 

  15. Baraldi E, Filippone M, Trevisanuto D, Zanardo V, Zacchello F. Pulmonary function until two years of life in infants with bronchopulmonary dysplasia. Am J Respir Crit Care Med 1997; 155: 149155.

    PubMed  CAS  Google Scholar 

  16. Mitchell SH, Teague WG. Reduced gas transfer at rest and during exercise in school-age survivors of bronchopulmonary dysplasia. Am J Respir Crit Care Med 1998; 157: 14061412.

    PubMed  CAS  Google Scholar 

  17. Santuz P, Baraldi E, Zaramella P, Filippone M, Zacchello F. Factors limiting exercise performance in long-term survivors of bronchopulmonary dysplasia. Am J Respir Crit Care Med 1995; 152: 12841289.

    PubMed  CAS  Google Scholar 

  18. Short EJ, Klein NK, Lewis BA et al. Cognitive and academic consequences of bronchopulmonary dysplasia and very low birth weight: 8-year-old outcomes. Pediatrics 2003; 112: e359.

    Article  PubMed  Google Scholar 

  19. Lewis BA, Singer LT, Fulton S et al. Speech and language outcomes of children with bronchopulmonary dysplasia. J Commun Disord 2002; 35: 393406.

    Article  PubMed  Google Scholar 

  20. Verder H, Albertsen P, Ebbesen F et al. Nasal continuous positive airway pressure and early surfactant therapy for respiratory distress syndrome in newborns of less than 30 weeks gestation. Pediatrics 1999; 103: E24.

    Article  PubMed  CAS  Google Scholar 

  21. Khalaf MN, Brodsky N, Hurley J, Bhandari V. A prospective randomized, controlled trial comparing synchronized nasal intermittent positive pressure ventilation versus nasal continuous positive airway pressure as modes of extubation. Pediatrics 2001; 108: 137.

    Article  PubMed  CAS  Google Scholar 

  22. Santin R, Brodsky N, Bhandari V. A prospective observational pilot study of synchronized nasal intermittent positive pressure ventilation (SNIPPV) as a primary mode of ventilation in infants > or = 28 weeks with respiratory distress syndrome (RDS). J Perinatol 2004; 24: 487493.

    Article  PubMed  Google Scholar 

  23. Mestan KK, Marks JD, Hecox K, Huo D, Schreiber MD. Neurodevelopmental outcomes of premature infants treated with inhaled nitric oxide. N Engl J Med 2005; 353: 2332.

    Article  PubMed  CAS  Google Scholar 

  24. Schreiber MD, Gin-Mestan K, Marks JD, Huo D, Lee G, Srisuparp P. Inhaled nitric oxide in premature infants with the respiratory distress syndrome. N Engl J Med 2003; 349: 2099107.

    Article  PubMed  CAS  Google Scholar 

  25. Field D, Elbourne D, Truesdale A et al. Neonatal Ventilation With Inhaled Nitric Oxide Versus Ventilatory Support Without Inhaled Nitric Oxide for Preterm Infants With Severe Respiratory Failure: the INNOVO multicentre randomised controlled trial (ISRCTN 17821339). Pediatr 2005; 115: 926936.

    Article  CAS  Google Scholar 

  26. Hascoet JM, Fresson J, Claris O et al. The safety and efficacy of nitric oxide therapy in premature infants. J Pediatr 2005; 146: 31823.

    Article  PubMed  CAS  Google Scholar 

  27. Davis JM, Rosenfeld WN, Richter SE et al. Safety and pharmacokinetics of multiple doses of recombinant human CuZn superoxide dismutase administered intratracheally to premature neonates with respiratory distress syndrome. Pediatrics 1997; 100: 2430.

    Article  PubMed  CAS  Google Scholar 

  28. Davis JM, Parad RB, Michele T, Allred E, Price A, Rosenfeld W. Pulmonary outcome at 1 year corrected age in premature infants treated at birth with recombinant human CuZn superoxide dismutase. Pediatrics 2003; 111: 469476.

    Article  PubMed  Google Scholar 

  29. Levine CR, Gewolb IH, Allen K et al. The safety, pharmacokinetics, and anti-inflammatory effects of intratracheal recombinant human Clara cell protein in premature infants with respiratory distress syndrome. Pediatr Res 2005; 58: 1521.

    Article  PubMed  CAS  Google Scholar 

  30. Dodd JM, Crowther CA, Cincotta R, Flenady V, Robinson JS. Progesterone supplementation for preventing preterm birth: a systematic review and meta-analysis. Acta Obstet Gynecol Scand 2005; 84: 526533.

    Article  PubMed  Google Scholar 

  31. Akram Khan M, Kuzma-Oreilly B, Brodsky NL, Bhandari V. Site-specific characteristics of infants developing bronchopulmonary dysplasia. J Perinatol 2006; 26: 428435.

    Article  PubMed  CAS  Google Scholar 

  32. Kulkarni A, Ehrenkranz RA, Bhandari V. Effect of introduction of synchronized nasal intermittent positive-pressure ventilation in a neonatal intensive care unit on bronchopulmonary dysplasia and growth in preterm infants. Am J Perinatol 2006; 23: 233240.

    Article  PubMed  Google Scholar 

  33. Bhandari V, Brodsky N, Porat R. Improved outcome of extremely low birth weight infants with Tegaderm application to skin. J Perinatol 2005; 25: 276281.

    Article  PubMed  Google Scholar 

  34. Bhandari V, Fall P, Raisz L, Rowe J. Potential biochemical growth markers in premature infants. Am J Perinatol 1999; 16: 339349.

    Article  PubMed  CAS  Google Scholar 

  35. Kamlin CO, Davis PG. Long versus short inspiratory times in neonates receiving mechanical ventilation. Cochrane Database Syst Rev 2004: CD004503.

  36. Yost CC, Soll RF. Early versus delayed selective surfactant treatment for neonatal respiratory distress syndrome. Cochrane Database Syst Rev 2000; CD001456.

  37. Schmidt B, Roberts RS, Davis P et al. Caffeine therapy for apnea of prematurity. N Engl J Med 2006; 354: 21122121.

    Article  PubMed  CAS  Google Scholar 

  38. Tyson JE, Wright LL, Oh W et al. Vitamin A supplementation for extremely-low-birth-weight infants. National Institute of Child Health and Human Development Neonatal Research Network. N Engl J Med 1999; 340: 19621968.

    Article  PubMed  CAS  Google Scholar 

  39. Halliday HL, Ehrenkranz RA, Doyle LW. Delayed (>3 weeks) postnatal corticosteroids for chronic lung disease in preterm infants. Cochrane Database Syst Rev 2003: CD001145.

  40. Halliday HL, Ehrenkranz RA, Doyle LW. Moderately early (714 days) postnatal corticosteroids for preventing chronic lung disease in preterm infants. Cochrane Database Syst Rev 2003: CD001144.

  41. Halliday HL, Ehrenkranz RA, Doyle LW. Early postnatal (<96 hours) corticosteroids for preventing chronic lung disease in preterm infants. Cochrane Database Syst Rev 2003: CD001146.

  42. Panitch HB, Keklikian EN, Motley RA, Wolfson MR, Schidlow DV. Effect of altering smooth muscle tone on maximal expiratory flows in patients with tracheomalacia. Pediatr Pulmonol 1990; 9: 170176.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Perinatal Medicine, Department of Pediatrics LCI 401B, Yale University School of Medicine, P.O. Box 208064, New Haven, CT, 06520-8064, USA

    Vineet Bhandari MD, DM

  2. Division of Pediatric Pulmonology, Connecticut Children’s Medical Center, New Haven, CT, USA

    Anita Bhandari

Authors
  1. Anita Bhandari
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Vineet Bhandari MD, DM
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Vineet Bhandari MD, DM.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bhandari, A., Bhandari, V. Bronchopulmonary dysplasia: An update. Indian J Pediatr 74, 73–77 (2007). https://doi.org/10.1007/s12098-007-0032-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12098-007-0032-z

Key words

Search

Navigation